US › Healthcare

AnaptysBio Inc (ANAB)

US · Healthcare · Biotechnology

$55.13+2.74%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$25.6M

Revenue YoY

-8.0%

Net profit

$-52.9M

Profit YoY

-34.5%

EPS

$-1.84

EPS estimate

$-1.07

Net margin

-206.9%

EPS came in at -1.84 against a street estimate of -1.07 — a miss of 72.3%.

Key statistics

Market cap

$1.58B

Forward P/E

0.0

P/B

124.01

Book value

$0.44

EPS (TTM)

$-1.02

52-week high

$72.36

52-week low

$11.40

50-day MA

$57.72

200-day MA

$42.25

Beta

0.38

Analyst view

Analysts rate AnaptysBio Inc a buy (10 buy, 2 hold, 0 sell out of 12) with an average price target of $87.09.

Shareholding

Insiders

5.68%

Institutions

100.82%

Largest institutional holders

Fund	Stake
EcoR1 Capital, LLC	26.61%
BlackRock Inc	5.68%
TANG CAPITAL MANAGEMENT LLC	4.49%
Morgan Stanley - Brokerage Accounts	3.36%
State Street Corp	3.35%
Affinity Asset Advisors, LLC	3.17%
Vanguard Capital Management, LLC	2.88%
Sanofi	2.78%

Recent filings & reports

Document	Date
Reg FD disclosure · Q3 2026	2026-07-30
Proxy statement · Q2 2026	2026-06-29
Material agreement · Q2 2026	2026-06-22
Reg FD disclosure · Q2 2026	2026-05-29
Charter / bylaws change · Q2 2026	2026-05-21
Quarterly report · Q1 2026	2026-05-12
Annual report FY2025	2026-03-03
Quarterly report · Q3 2025	2025-11-04

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for AnaptysBio Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.